Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study

Joong Won Park, Minshan Chen, Massimo Colombo, Lewis Rowland Roberts, Myron Schwartz, Pei Jer Chen, Masatoshi Kudo, Philip Johnson, Samuel Wagner, Lucinda S. Orsini, Morris Sherman

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.

Original languageEnglish (US)
Pages (from-to)2155-2166
Number of pages12
JournalLiver International
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Hepatocellular Carcinoma
North America
Republic of Korea
Taiwan
China
Japan
Survival
Liver Neoplasms
Hepatitis B virus
Hepacivirus
Longitudinal Studies
Cause of Death
Cohort Studies
Ethanol
Therapeutics
Demography
Injections
Neoplasms

Keywords

  • Disease management
  • Epidemiology
  • Global trends
  • Liver cancer
  • Observational study
  • Risk factors
  • Treatment patterns

ASJC Scopus subject areas

  • Hepatology

Cite this

Global patterns of hepatocellular carcinoma management from diagnosis to death : The BRIDGE Study. / Park, Joong Won; Chen, Minshan; Colombo, Massimo; Roberts, Lewis Rowland; Schwartz, Myron; Chen, Pei Jer; Kudo, Masatoshi; Johnson, Philip; Wagner, Samuel; Orsini, Lucinda S.; Sherman, Morris.

In: Liver International, Vol. 35, No. 9, 01.09.2015, p. 2155-2166.

Research output: Contribution to journalArticle

Park, JW, Chen, M, Colombo, M, Roberts, LR, Schwartz, M, Chen, PJ, Kudo, M, Johnson, P, Wagner, S, Orsini, LS & Sherman, M 2015, 'Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study', Liver International, vol. 35, no. 9, pp. 2155-2166. https://doi.org/10.1111/liv.12818
Park, Joong Won ; Chen, Minshan ; Colombo, Massimo ; Roberts, Lewis Rowland ; Schwartz, Myron ; Chen, Pei Jer ; Kudo, Masatoshi ; Johnson, Philip ; Wagner, Samuel ; Orsini, Lucinda S. ; Sherman, Morris. / Global patterns of hepatocellular carcinoma management from diagnosis to death : The BRIDGE Study. In: Liver International. 2015 ; Vol. 35, No. 9. pp. 2155-2166.
@article{3233ed8ba5604e108a4a9fcb690706be,
title = "Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study",
abstract = "Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67{\%} of patients, Europe for 20{\%} and North America for 13{\%}. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.",
keywords = "Disease management, Epidemiology, Global trends, Liver cancer, Observational study, Risk factors, Treatment patterns",
author = "Park, {Joong Won} and Minshan Chen and Massimo Colombo and Roberts, {Lewis Rowland} and Myron Schwartz and Chen, {Pei Jer} and Masatoshi Kudo and Philip Johnson and Samuel Wagner and Orsini, {Lucinda S.} and Morris Sherman",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/liv.12818",
language = "English (US)",
volume = "35",
pages = "2155--2166",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Global patterns of hepatocellular carcinoma management from diagnosis to death

T2 - The BRIDGE Study

AU - Park, Joong Won

AU - Chen, Minshan

AU - Colombo, Massimo

AU - Roberts, Lewis Rowland

AU - Schwartz, Myron

AU - Chen, Pei Jer

AU - Kudo, Masatoshi

AU - Johnson, Philip

AU - Wagner, Samuel

AU - Orsini, Lucinda S.

AU - Sherman, Morris

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.

AB - Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results: Forty-two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001). Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.

KW - Disease management

KW - Epidemiology

KW - Global trends

KW - Liver cancer

KW - Observational study

KW - Risk factors

KW - Treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=84984564079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984564079&partnerID=8YFLogxK

U2 - 10.1111/liv.12818

DO - 10.1111/liv.12818

M3 - Article

C2 - 25752327

AN - SCOPUS:84984564079

VL - 35

SP - 2155

EP - 2166

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 9

ER -